phrykt

REGENXBIO Inc. (RGNX): who owns it and who trades it

As of Nov 16, 2026, RGNX insiders reported 5 open-market sales worth $940K and 2 purchases worth $950K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Steve Pakola (Chief Medical Officer), with $940K. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling REGENXBIO

From the latest filings

Overall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns RGNX

164 funds and institutions reported RGNX shares worth $511M at the end of Q2 2026, about 83% of the company. The largest holder is BlackRock, Inc. with 12.4%.

Funds and institutions (13F) 83%Everyone else 17%

10 largest owners, by share of the company

BlackRock, Inc.12.4%
Redmile Group, LLC8.5%
State Street Corp5.8%
JPMorgan Chase & Co4.3%
Vanguard Capital Management LLC4.1%
Morgan Stanley3.8%
Goldman Sachs Group Inc2.8%
AQR Capital Management LLC2.7%
Vanguard Portfolio Management LLC2.6%
Marshall Wace, LLP2.5%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.6.40M12.40%$76.6M+11%
Redmile Group, LLC4.37M8.46%$52.3MNo change
State Street Corp2.97M5.76%$35.6M+9%
JPMorgan Chase & Co2.21M4.29%$26.2M–
Vanguard Capital Management LLC2.11M4.08%$25.2M+5%
Morgan Stanley1.95M3.78%$23.4M-5%
Goldman Sachs Group Inc1.42M2.75%$17M-23%
AQR Capital Management LLC1.38M2.67%$16.5M+31%
Vanguard Portfolio Management LLC1.36M2.63%$16.2M+33%
Marshall Wace, LLP1.28M2.49%$15.4M–
Geode Capital Management, LLC1.24M2.41%$14.9M+9%
Integral Health Asset Management, LLC800,0001.55%$9.6M-47%
Nuveen, LLC740,0261.43%$8.9M+27%
Dimensional Fund Advisors LP731,5861.42%$8.8M-28%
D. E. Shaw & Co., Inc.712,8141.38%$8.5M+149%
Two Sigma Investments, LP669,8081.30%$8M+21%
Citadel Advisors LLC669,0231.30%$8M–
Stifel Financial Corp560,7271.09%$6.7M+43%
Bank of America Corp518,5451.00%$6.2M+60%
22nw, LP492,7590.95%$5.9MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, RGNX insiders reported $950K of open-market purchases and $940K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$950K
2 trades, 1 people
Sales, 12 months
$940K
5 trades, 1 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Aug 27, 2026
Filed Aug 27, 2026

Purchases and sales by month

$950K$950KDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Aug 27, 2026Gregory Austin CiongoliDirectorPurchase53,407$9.36$500KForm 4
Aug 26, 2026Gregory Austin CiongoliDirectorPurchase49,196$9.14$450KForm 4
Jul 2, 2026Steve PakolaChief Medical OfficerSale2,161$13.64$29.5KForm 4
Jul 1, 2026Steve PakolaChief Medical OfficerSale36,725$12.86$472KForm 4
Jun 29, 2026Steve PakolaChief Medical OfficerSale19,608$11.04$216KForm 4
May 11, 2026Steve PakolaChief Medical OfficerSale15,309$11.02$169KForm 4
Mar 10, 2026Steve PakolaChief Medical OfficerSale5,124$10.35$53KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Gregory Austin CiongoliDirector$950K–Aug 27, 2026
Steve PakolaChief Medical Officer–$940KJul 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

RGNX short interest

High short interest. 15.4% of RGNX shares are sold short: about 1 share in 6. Over the last 12 reports the number of shares short went up 43%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 10.18M RGNX shares were sold short, 15.4% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 1.23M shares, buying them all back would take about 8.3 trading days (days to cover).

Shares short, % of all shares

15.4%May 15Oct 3021.7%

Days to cover

8.3May 15Oct 309.1

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202610.18M15.40%+1%1.23M8.3
Oct 15, 202610.04M15.21%+5%1.48M6.8
Sep 30, 20269.61M14.56%+21%1.60M6.0
Sep 15, 20267.93M12.01%+6%1.03M7.7
Aug 31, 20267.50M11.36%-9%1.54M4.9
Aug 14, 20268.20M12.42%+14%1.06M7.8
Jul 31, 20267.19M10.90%-17%1.90M3.8
Jul 15, 20268.63M16.71%-18%2.62M3.3
Jun 30, 202610.46M20.27%+13%3.28M3.2
Jun 15, 20269.26M17.95%+12%1.33M7.0
May 29, 20268.28M16.05%+16%1.84M4.5
May 15, 20267.14M13.83%+7%2.23M3.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

REGENXBIO company events

REGENXBIO filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 5, 2026.

  1. Nov 5, 2026ResultsReleased financial results. Filing
  2. Oct 16, 2026LeadershipKenneth T. Mills resigned from the board of directors of REGENXBIO Inc. effective October 21, 2026. Filing
  3. Sep 23, 2026AgreementREGENXBIO Inc. and The Trustees of the University of Pennsylvania entered into a Settlement Agreement with Sarepta Therapeutics, Inc. and Sarepta Therapeutics Three, LLC (together with Sarepta Therapeutics, Inc., “Sarepta”) and Catalent, Inc. to resolve all patent infringement litigation alleging… Filing
  4. Aug 25, 2026LeadershipThe Board of Directors of REGENXBIO Inc., elected Gregory Ciongoli as a Class II director of the Company effective immediately. Filing
  5. Aug 24, 2026AnnouncementThe Company announced that it received communication from the FDA that the Company’s Investigational New Drug application for its Phase I/II/III trial of RGX-121 for MPS II was placed on clinical hold and that the Company does not expect to resubmit the RGX-121 BLA in the near term. Filing
  6. Aug 6, 2026ResultsReleased financial results. Filing
  7. Jul 20, 2026AnnouncementREGENXBIO Inc. entered into an underwriting agreement with Morgan Stanley & Co. LLC, J.P. Morgan Securities LLC, Leerink Partners LLC and Mizuho Securities USA LLC, as representatives of the several underwriters named therein, relating to the offer and sale of 10,003,889 shares of the Company’s… Filing
  8. Jun 29, 2026AnnouncementREGENXBIO Inc. announced that it has earned a milestone payment of $100.0 million from AbbVie Global Enterprises Ltd., a subsidiary of AbbVie Inc., pursuant to the Collaboration and License Agreement, dated as of September 10, 2021 between the Company and AbbVie, as amended on August 5, 2025. Filing
  9. Jun 3, 2026AnnouncementThe Company commenced a Stock Option Exchange Program for non-executive employees that was approved by shareholders at the Annual Meeting. Filing
  10. May 14, 2026AnnouncementThe Company issued a press release announcing topline and interim analysis of data from the AFFINITY DUCHENNE RGX-202 trial. Filing
  11. Mar 20, 2026AgreementREGENXBIO Inc. entered into a Settlement and Release Agreement with GlaxoSmithKline LLC to resolve non-binding mediation related to the License Agreement dated March 6, 2009, as amended on April 15, 2009, between GSK and the Company (as amended, the “GSK-REGENXBIO Sublicense”). Filing
  12. Mar 5, 2026ResultsReleased financial results. Filing
  13. Feb 10, 2026AnnouncementThe Company received a CRL from the FDA regarding the Company’s BLA for RGX-121, the Company's investigational gene therapy for Mucopolysaccharidosis type II. Item 9.01. Filing
  14. Jan 28, 2026AnnouncementREGENXBIO Inc. announced that it received communication from the U.S. Food and Drug Administration that the Company’s Investigational New Drug applications for both its Phase I/II trial evaluating RGX-111 for Mucopolysaccharidosis type I and its Phase I/II/III trial of RGX-121 for… Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

REGENXBIO financials

Famous investors that hold RGNX

5 of the 50 well-known investors we track reported holding RGNX in their latest 13F filing. The largest position is Ken Griffin's, worth $8.4M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Ken Griffin · Citadel AdvisorsQ3 20261.11M$8.4M0.0%+66%
Steve Cohen · Point72 Asset ManagementQ3 2026668,463$5M0.0%New
Israel Englander · Millennium ManagementQ3 2026502,707$3.8M0.0%+5%
Jim Simons · Renaissance TechnologiesQ3 2026117,986$888K0.0%-54%
Paul Tudor Jones · Tudor Investment CorpQ3 202630,248$228K0.0%+27%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named RGNX in the last 120 days.

FiledHolderFormStake
Nov 10, 2026STATE STREET CORPORATION13G4.8%
Nov 10, 2026STATE STREET CORPORATION13G4.8%
Oct 13, 2026JPMORGAN CHASE & CO.13G5.3%
Oct 13, 2026JPMORGAN CHASE & CO.13G5.3%

Questions about REGENXBIO Inc. (RGNX) stock

Who owns the most RGNX stock?

The largest reported owner of REGENXBIO Inc. (RGNX) is BlackRock, Inc., with 12.4% of the company. In total, 164 funds and institutions reported holding RGNX at the end of Q2 2026, together about 83% of the shares. See the largest owners.

Are RGNX insiders buying or selling?

In the last 12 months, RGNX insiders reported 2 open-market purchases worth $950K and 5 sales worth $940K. The latest trade was on Aug 27, 2026. See every trade.

What is the short interest in RGNX?

As of Oct 30, 2026, 10.18M RGNX shares were sold short, 15.4% of the shares outstanding, up 1.4% from the report before. At the average daily volume of 1.23M shares, buying them all back would take about 8.3 trading days (days to cover). See the history.

Which famous investors hold RGNX?

5 of the 50 well-known investors we track reported RGNX in their latest 13F filing, including Ken Griffin, Steve Cohen, Israel Englander. The largest position is worth $8.4M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.